| [1] |
Morris ME, Rodriguez-Cruz V, Felmlee MA.
SLC and ABC Transporters: Expression, Localization, and Species Differences at the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers[J]. AAPS JAAPS J, 2017, 19(5): 1317-1331.
doi: 10.1208/s12248-017-0110-8 |
| [2] |
Aleksandra A, Falasca M, et al.
ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?[J]. World J GastroenterolWorld J Gastroenterol, 2018, 24(29): 3222-3238.
doi: 10.3748/wjg.v24.i29.3222 |
| [3] |
Juliano RL, Ling V.
A Surface Glycoprotein Modulating Drug Permeability in Chinese Hamster Ovary Cell Mutants[J]. Biochim Biophys ActaBiochim Biophys Acta, 1976, 455(1): 152-162.
doi: 10.1016/0005-2736(76)90160-7 |
| [4] |
Mairinger S, Erker T, Müller M, et al.
PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters In Vivo[J]. Curr Drug MetabCurr Drug Metab, 2011, 12(8): 774-792.
doi: 10.2174/138920011798356980 |
| [5] |
Holohan C, Van Schaeybroeck S, Longley DB, et al.
Cancer drug resistance: an evolving paradigm[J]. Nat Rev CancerNat Rev Cancer, 2013, 13(10): 714-726.
doi: 10.1038/nrc3599 |
| [6] |
Lin G, Mi P, Chu CC, et al. Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics[J/OL]. Adv Sci, 2016, 3(11): 1600134[2018-12-27]. https://onlinelibrary.wiley.com/doi/full/10.1002/advs.201600134. DOI: 10.1002/advs.201600134. |
| [7] |
Gomes BC, Honrado M, Armada AM, et al.
ABC Efflux Transporters and the Circuitry of miRNAs: Kinetics of Expression in Cancer Drug Resistance[J]. Int J Mol SciInt J Mol Sci, 2020, 21(8): 2985-.
doi: 10.3390/ijms21082985 |
| [8] |
Fox E, Bates SE.
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor[J]. Expert Rev Anticancer TherExpert Rev Anticancer Ther, 2007, 7(8): 447-459.
doi: 10.15861/14737140.7.4.447 |
| [9] |
Leopoldo M, Nardulli P, Contino M, et al.
An updated patent review on P-glycoprotein inhibitors (2011-2018)[J]. Expert Opinion on Therapeutic Patents,Expert Opinion on Therapeutic Patents,, 2019, 29(6): 455-461.
doi: 10.1080/13543776.2019.1618273. |
| [10] |
Cole SP, Bhardwaj G, Gerlach JH, et al.
Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line[J]. ScienceScience, 1992, 258(5088): 1650-1654.
doi: 10.1126/science.1360704 |
| [11] |
Chen YN, Mickley LA, Schwartz AM, et al.
Characterization of Adriamycin-Resistant Human Breast Cancer Cells Which Display Overexpression of a Novel Resistance-Related Membrane Protein[J]. J Biol ChemJ Biol Chem, 1990, 265(17): 10073-10080.
|
| [12] |
Dean M, Rzhetsky A, Allikmets R.
The Human ATP-Binding Cassette(ABC) Transporter Superfamily[J]. Genome ResGenome Res, 2001, 11(7): 1156-1166.
doi: 10.1101/gr.184901 |
| [13] |
Sivapackiam J, Harpstrite SE, Prior JL, et al.
67/68Galmydar: A metalloprobe for monitoring breast cancer resistance protein (BCRP)-mediated functional transport activity[J]. Nucl Med BiolNucl Med Biol, 2016, 43(3): 191-197.
doi: 10.1016/j.nucmedbio.2015.12.001 |
| [14] |
Nakayama A, Matsuo H, Takada T, et al.
ABCG2 is a High-Capacity Urate Transporter and its Genetic Impairment Increases Serum Uric Acid Levels in Humans[J]. Nucleosides Nucleotides Nucleic AcidsNucleosides Nucleotides Nucleic Acids, 2011, 30(12): 1091-1097.
doi: 10.1080/15257770.2011.633953 |
| [15] |
Weidner LD, Zoghbi SS, Lu SY, et al.
The Inhibitor Ko143 Is Not Specific for ABCG2[J]. J Pharmacol Exp TherJ Pharmacol Exp Ther, 2015, 354(3): 384-393.
doi: 10.1124/jpet.115.225482 |
| [16] |
Shen Y, Chen W, Zhao B, et al. CS1 is a novel topoisomerase IIα inhibitor with favorable drug resistance profiles[J]. Biochemical and Biophysical Research Communications, 2014, 453(3): 302−308. |
| [17] |
Alpsoy A, Yasa S, Gündüz U.
Etoposide resistance in MCF-7 breast cancer cell line is marked by multiple mechanisms[J]. Biomed PharmacotherBiomed Pharmacother, 2014, 68(3): 351-355.
doi: 10.1016/j.biopha.2013.09.007 |
| [18] |
Huang F, Li SJ, Lu XH, et al.
Two glutathione S-transferase inhibitors from Radix Angelicae sinensis[J]. Phytother ResPhytother Res, 2011, 25(2): 284-289.
doi: 10.1002/ptr.3197 |
| [19] |
Mann A, Semenenko I, Meir M, et al.
Molecular Imaging of Membrane Transporters' Activity in Cancer: a Picture is Worth a Thousand Tubes[J]. AAPS JAAPS J, 2015, 17(4): 788-801.
doi: 10.1208/s12248-015-9752-6 |
| [20] |
Sivapackiam J, Gammon ST, Harpstrite SE, et al. Targeted Chemotherapy in Drug-Resistant Tumors, Noninvasive Imaging of P-Glycoprotein-Mediated Functional Transport in Cancer, and Emerging Role of Pgp in Neurodegenerative Diseases[M]//Zhou J. Methods in Molecular Biology. Totowa: Humana Press, 2010: 141−181. DOI: 10.1007/978−1−60761−416−6_8. |
| [21] |
Levchenko A, Mehta BM, Lee JB, et al.
Evaluation of 11C-Colchicine for PET Imaging of Multiple Drug Resistance[J]. J Nucl MedJ Nucl Med, 2000, 41(3): 493-501.
|
| [22] |
Kannan P, Füredi A, Dizdarevic S, et al. In vivo characterization of [18F]AVT-011 as a radiotracer for PET imaging of multidrug resistance[J/OL]. Eur J Nucl Med Mol Imaging, 2019[2018-12-28]. https://link.springer.com/content/pdf/10.1007/s00259-019-04589-w.pdf. [published online ahead of print November 15, 2019]. DOI: 10.1007/s00259−019−04589−w. |
| [23] |
Römermann K, Wanek T, Bankstahl M, et al.
(R)--[11C]verapamil is selectively transported by murine and human P-glycoprotein at the blood–brain barrier, and not by MRP1 and BCRP[J]. Nucl Med BiolNucl Med Biol, 2013, 40(7): 873-878.
doi: 10.1016/j.nucmedbio.2013.05.012 |
| [24] |
Bauer M, Wulkersdorfer B, Karch R, et al.
Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[11C]verapamil in elderly vs. young subjects[J]. Bri J Clin PharmacolBri J Clin Pharmacol, 2017, 83(9): 1991-1999.
doi: 10.1111/bcp.13301 |
| [25] |
陈伟君, 孙达.
99Tcm-MIBI显像在乳腺癌新辅助化疗中的应用价值[J]. 国际放射医学核医学杂志国际放射医学核医学杂志, 2015, 39(6): 487-492.
Chen WJ, Sun D. Clinical value of 99Tcm-MIBI imaging in neoadjuvant chemotherapy of breast cancer[J]. Int J Radiat Med Nucl MedInt J Radiat Med Nucl Med, 2015, 39(6): 487-492. |
| [26] |
Dizdarevic S, Peters AM.
Imaging of multidrug resistance in cancer[J]. Cancer ImagingCancer Imaging, 2011, 11(1): 1-8.
doi: 10.1102/1470-7330.2011.0001 |
| [27] |
Fox E, Widemann BC, Pastakia D, et al.
Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors[J]. Cancer Chemother PharmacolCancer Chemother Pharmacol, 2015, 76(6): 1273-1283.
doi: 10.1007/s00280-015-2845-10 |
| [28] |
Borst P, Evers R, Kool M, et al.
A Family of Drug Transporters: the Multidrug Resistance-Associated Proteins[J]. J Natil Cancer InstJ Natil Cancer Inst, 2000, 92(16): 1295-1302.
doi: 10.1093/jnci/92.16.1295 |
| [29] |
Nagengast WB, Oude Munnink TH, Dijkers EC, et al. Multidrug Resistance in Oncology and Beyond: From Imaging of Drug Efflux Pumps to Cellular Drug Targets[M]//Zhou J. Methods in Molecular Biology. Totowa: Humana Press, 2010: 15−31. DOI: 10.1007/978−1−60761−416−6_2. |
| [30] |
Qawasmi I, Shmuel M, Eyal S. Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging[J/OL]. Front Pharmacol, 2014, 5: 257[2018-12-27]. https://www.frontiersin.org/articles/10.3389/fphar.2014.00257/full. DOI: 10.3389/fphar.2014.00257. |
| [31] |
Eadie LN, Hughes TP, White DL.
Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib[J]. Clin Pharmacol TherClin Pharmacol Ther, 2014, 95(3): 294-306.
doi: 10.1038/clpt.2013.208 |
| [32] |
Dörner B, Kuntner C, Bankstahl JP, et al.
Synthesis and Small-Animal Positron Emission Tomography Evaluation of [11C]-Elacridar As a Radiotracer to Assess the Distribution of P-Glycoprotein at the Blood?Brain Barrier[J]. J Med ChemJ Med Chem, 2009, 52(19): 6073-6082.
doi: 10.1021/jm900940f |
| [33] |
Kawamura K, Konno F, Yui J, et al.
Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET[J]. Ann Nucl MedAnn Nucl Med, 2010, 24(5): 403-412.
doi: 10.1007/s12149-010-0373-y |
| [34] |
Kannan P, Telu S, Shukla S, et al.
The "Specific" P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2)[J]. ACS Chem NeurosciACS Chem Neurosci, 2011, 2(2): 82-89.
doi: 10.1021/cn100078a |
| [35] |
Mairinger S, Zoufal V, Wanek T, et al.
Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice[J]. Eur J Pharm SciEur J Pharm Sci, 2018, 115: 212-222.
doi: 10.1016/j.ejps.2018.01.034 |
| [36] |
Kikuchi T, Okamura T, Okada M, et al.
Benzyl [11C]Hippurate as an Agent for Measuring the Activities of Organic Anion Transporter 3 in the Brain and Multidrug Resistance-Associated Protein 4 in the Heart of Mice[J]. J Med ChemJ Med Chem, 2016, 59(12): 5847-5856.
doi: 10.1021/acs.jmedchem.6b00454 |
| [37] |
Okamura T, Kikuchi T, Fukushi K, et al.
A novel noninvasive method for assessing glutathione-conjugate efflux systems in the brain[J]. Bioorg Med ChemBioorg Med Chem, 2007, 15(9): 3127-3133.
doi: 10.1016/j.bmc.2007.02.045 |
| [38] |
Galante E, Okamura T, Sander K, et al.
Development of Purine-Derived 18F-Labeled Pro-drug Tracers for Imaging of MRP1 Activity with PET[J]. J Med ChemJ Med Chem, 2014, 57(3): 1023-1032.
doi: 10.1021/jm401764a |
| [39] |
Okamura T, Kikuchi T, Okada M, et al.
Noninvasive and Quantitative Assessment of the Function of Multidrug Resistance-Associated Protein 1 in the Living Brain[J]. J Cereb Blood Flow MetabJ Cereb Blood Flow Metab, 2009, 29(3): 504-511.
doi: 10.1038/jcbfm.2008.135 |
| [40] |
Wang MZ, Mao CQ, Wang H, et al.
Molecular Imaging of P-Glycoprotein in Chemoresistant Tumors Using a Dual-Modality Pet/Fluorescence Probe[J]. Mol PharmaceuticsMol Pharmaceutics, 2017, 14(10): 3391-3398.
doi: 10.1021/acs.molpharmaceut.7b00420 |
| [41] |
On NH, Chen F, Hinton M, et al.
Assessment of P-Glycoprotein Activity in the Blood-Brain Barrier (BBB) Using Near Infrared Fluorescence (NIRF) Imaging Techniques[J]. Pharm ResPharm Res, 2011, 28(10): 2505-2515.
doi: 10.1007/s11095-011-0478-6 |
| [42] |
Semenenko I, Portnoy E, Aboukaoud M, et al. Evaluation of Near Infrared Dyes as Markers of P-Glycoprotein Activity in Tumors[J/OL]. Front Pharmacol, 2016, 7: 426[2018-12-27]. https://www.frontiersin.org/articles/10.3389/fphar.2016.00426/full. DOI: 10.3389/fphar.2016.00426. |
| [43] |
Bakhsheshian J, Wei BR, Chang KE, et al.
Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2[J]. Proc Natl Acad Sci USAProc Natl Acad Sci USA, 2013, 110(51): 20801-20806.
doi: 10.1073/pnas.1312159110 |
| [44] |
Sun Y, Gu MC, Zhu LX, et al.
Gemcitabine upregulates ABCG2/BCRP and modulates the intracellular pharmacokinetic profiles of bioluminescence in pancreatic cancer cells[J]. Anti-Cancer DrugsAnti-Cancer Drugs, 2016, 27(3): 183-191.
doi: 10.1097/CAD.0000000000000315 |
| [45] |
Saito S, Obata A, Kashiwagi Y, et al.
Dynamic Contrast-Enhanced MRI of the Liver in Mrp2-Deficient Rats Using the Hepatobiliary Contrast Agent Gd-EOB-DTPA[J]. Invest RadiolInvest Radiol, 2013, 48(7): 548-553.
doi: 10.1097/RLI.0b013e3182856a06 |
| [46] |
Noguchi K, Katayama K, Sugimoto Y.
Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics[J]. Pharmgenomics Pers MedPharmgenomics Pers Med, 2014, 7: 53-64.
doi: 10.2147/PGPM.S38295 |